42,778 Shares in Disc Medicine, Inc. $IRON Acquired by NEXTBio Capital Management LP

NEXTBio Capital Management LP bought a new position in Disc Medicine, Inc. (NASDAQ:IRON) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 42,778 shares of the company’s stock, valued at approximately $3,397,000. Disc Medicine comprises about 2.0% of NEXTBio Capital Management LP’s holdings, making the stock its 19th largest holding.

Several other hedge funds have also modified their holdings of IRON. JPMorgan Chase & Co. boosted its position in shares of Disc Medicine by 110.0% in the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after acquiring an additional 828,248 shares during the last quarter. Jennison Associates LLC acquired a new stake in shares of Disc Medicine in the fourth quarter worth approximately $42,252,000. Pictet Asset Management Holding SA boosted its position in shares of Disc Medicine by 10,968.6% in the fourth quarter. Pictet Asset Management Holding SA now owns 394,374 shares of the company’s stock worth $31,317,000 after acquiring an additional 390,811 shares during the last quarter. Vestal Point Capital LP boosted its position in shares of Disc Medicine by 257.1% in the third quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock worth $33,040,000 after acquiring an additional 360,000 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Disc Medicine by 3,329.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock worth $28,416,000 after acquiring an additional 347,403 shares during the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Stifel Nicolaus decreased their target price on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Wedbush reissued an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a research report on Wednesday. BMO Capital Markets decreased their target price on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 17th. Finally, Morgan Stanley lifted their price target on shares of Disc Medicine from $75.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $105.30.

Insider Buying and Selling

In other Disc Medicine news, CFO Jean M. Franchi sold 6,257 shares of Disc Medicine stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the transaction, the chief financial officer directly owned 64,333 shares of the company’s stock, valued at $4,454,416.92. The trade was a 8.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider William Jacob Savage sold 5,731 shares of Disc Medicine stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $66.38, for a total transaction of $380,423.78. Following the transaction, the insider directly owned 79,480 shares in the company, valued at approximately $5,275,882.40. This trade represents a 6.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 12,388 shares of company stock worth $841,258. 3.76% of the stock is currently owned by corporate insiders.

Disc Medicine Trading Down 0.1%

Shares of IRON stock opened at $67.99 on Friday. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of -10.27 and a beta of 0.93. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The firm’s 50 day moving average price is $68.16 and its two-hundred day moving average price is $72.57.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). On average, analysts anticipate that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.